Foghorn Therapeutics Analyst Ratings
Foghorn Therapeutics Analyst Ratings
While ratings are subjective and will change, the latest Foghorn Therapeutics (FHTX) rating was a maintained with a price target of $10.00 to $6.00. The current price Foghorn Therapeutics (FHTX) is trading at is $3.23, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/13/2023 | 85.76% | Morgan Stanley | $10 → $6 | Maintains | Equal-Weight |
| 08/07/2023 | 519.2% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 07/06/2023 | 209.6% | Morgan Stanley | $13 → $10 | Maintains | Equal-Weight |
| 06/29/2023 | 488.24% | Goldman Sachs | $21 → $19 | Maintains | Buy |
| 06/28/2023 | 519.2% | HC Wainwright & Co. | $20 → $20 | Reiterates | Buy → Buy |
| 06/08/2023 | 519.2% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 05/09/2023 | 333.44% | Wedbush | $15 → $14 | Maintains | Outperform |
| 05/09/2023 | 519.2% | HC Wainwright & Co. | $25 → $20 | Maintains | Buy |
| 04/25/2023 | 488.24% | BMO Capital | $20 → $19 | Maintains | Outperform |
| 04/25/2023 | 364.4% | Wedbush | $20 → $15 | Maintains | Outperform |
| 03/28/2023 | 209.6% | B of A Securities | → $10 | Initiates Coverage On | → Buy |
| 03/10/2023 | 673.99% | HC Wainwright & Co. | → $25 | Reiterates | → Buy |
| 03/10/2023 | 519.2% | Wedbush | $25 → $20 | Maintains | Outperform |
| 01/05/2023 | 519.2% | BMO Capital | → $20 | Initiates Coverage On | → Outperform |
| 11/21/2022 | 333.44% | Morgan Stanley | $15 → $14 | Maintains | Equal-Weight |
| 08/24/2022 | 364.4% | Morgan Stanley | $25 → $15 | Downgrades | Overweight → Equal-Weight |
| 08/10/2022 | 673.99% | HC Wainwright & Co. | $18 → $25 | Maintains | Buy |
| 05/24/2022 | 550.15% | Goldman Sachs | $30 → $21 | Maintains | Buy |
| 05/23/2022 | 673.99% | Morgan Stanley | $26 → $25 | Maintains | Overweight |
| 05/20/2022 | 457.28% | HC Wainwright & Co. | $25 → $18 | Maintains | Buy |
| 12/15/2021 | 704.95% | Morgan Stanley | $23 → $26 | Maintains | Overweight |
| 11/22/2021 | 673.99% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 03/23/2021 | 612.07% | Morgan Stanley | $24 → $23 | Maintains | Overweight |
| 11/17/2020 | 643.03% | Wedbush | → $24 | Initiates Coverage On | → Outperform |
| 11/17/2020 | 643.03% | Morgan Stanley | → $24 | Initiates Coverage On | → Overweight |
| 11/17/2020 | 735.91% | Goldman Sachs | → $27 | Initiates Coverage On | → Buy |
| 11/17/2020 | — | Cowen & Co. | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/13/2023 | 85.76% | 摩根士丹利 | 10 美元 → 6 美元 | 維護 | 重量相等 |
| 08/07/2023 | 519.2% | HC Wainwright & Co. | → 20 美元 | 重申 | 購買 → 購買 |
| 07/06/2023 | 209.6% | 摩根士丹利 | 13 美元 → 10 美元 | 維護 | 重量相等 |
| 06/29/2023 | 488.24% | 高盛 | 21 美元 → 19 美元 | 維護 | 買 |
| 06/28/2023 | 519.2% | HC Wainwright & Co. | 20 美元 → 20 美元 | 重申 | 購買 → 購買 |
| 06/08/2023 | 519.2% | HC Wainwright & Co. | → 20 美元 | 重申 | 購買 → 購買 |
| 05/09/2023 | 333.44% | Wedbush | 15 美元 → 14 美元 | 維護 | 跑贏大盤 |
| 05/09/2023 | 519.2% | HC Wainwright & Co. | 25 美元 → 20 美元 | 維護 | 買 |
| 2023 年 4 月 25 日 | 488.24% | BMO Capital | 20 美元 → 19 美元 | 維護 | 跑贏大盤 |
| 2023 年 4 月 25 日 | 364.4% | Wedbush | 20 美元 → 15 美元 | 維護 | 跑贏大盤 |
| 03/28/2023 | 209.6% | B of A 類證券 | → 10 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 03/10/2023 | 673.99% | HC Wainwright & Co. | → 25 美元 | 重申 | → 購買 |
| 03/10/2023 | 519.2% | Wedbush | 25 美元 → 20 美元 | 維護 | 跑贏大盤 |
| 01/05/2023 | 519.2% | BMO Capital | → 20 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 11/21/2022 | 333.44% | 摩根士丹利 | 15 美元 → 14 美元 | 維護 | 重量相等 |
| 2022 年 8 月 24 日 | 364.4% | 摩根士丹利 | 25 美元 → 15 美元 | 降級 | 超重 → 重量相等 |
| 08/10/2022 | 673.99% | HC Wainwright & Co. | 18 美元 → 25 美元 | 維護 | 買 |
| 2022 年 5 月 24 日 | 550.15% | 高盛 | 30 美元 → 21 美元 | 維護 | 買 |
| 05/23/2022 | 673.99% | 摩根士丹利 | 26 美元 → 25 美元 | 維護 | 超重 |
| 05/20/2022 | 457.28% | HC Wainwright & Co. | 25 美元 → 18 美元 | 維護 | 買 |
| 2021 年 12 月 15 日 | 704.95% | 摩根士丹利 | 23 美元 → 26 美元 | 維護 | 超重 |
| 11/22/2021 | 673.99% | HC Wainwright & Co. | → 25 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 03/23/2021 | 612.07% | 摩根士丹利 | 24 美元 → 23 美元 | 維護 | 超重 |
| 2020 年 11 月 17 日 | 643.03% | Wedbush | → 24 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 2020 年 11 月 17 日 | 643.03% | 摩根士丹利 | → 24 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 2020 年 11 月 17 日 | 735.91% | 高盛 | → 27 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2020 年 11 月 17 日 | — | Cowen & Co. | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
What is the target price for Foghorn Therapeutics (FHTX)?
Foghorn Therapeutics（FHTX）的目標價格是多少？
The latest price target for Foghorn Therapeutics (NASDAQ: FHTX) was reported by Morgan Stanley on November 13, 2023. The analyst firm set a price target for $6.00 expecting FHTX to rise to within 12 months (a possible 85.76% upside). 15 analyst firms have reported ratings in the last year.
摩根士丹利於2023年11月13日公佈了Foghorn Therapeutics（納斯達克股票代碼：FHTX）的最新目標股價。該分析公司將目標股價定爲6.00美元，預計FHTX將在12個月內升至12個月內（可能上漲85.76％）。去年有15家分析公司公佈了評級。
What is the most recent analyst rating for Foghorn Therapeutics (FHTX)?
Foghorn Therapeutics（FHTX）的最新分析師評級是多少？
The latest analyst rating for Foghorn Therapeutics (NASDAQ: FHTX) was provided by Morgan Stanley, and Foghorn Therapeutics maintained their equal-weight rating.
摩根士丹利對Foghorn Therapeutics（納斯達克股票代碼：FHTX）的最新分析師評級由摩根士丹利提供，Foghorn Therapeutics維持同等權重評級。
When is the next analyst rating going to be posted or updated for Foghorn Therapeutics (FHTX)?
Foghorn Therapeutics（FHTX）的下一份分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Foghorn Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Foghorn Therapeutics was filed on November 13, 2023 so you should expect the next rating to be made available sometime around November 13, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Foghorn Therapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Foghorn Therapeutics的最新評級是在2023年11月13日公佈的，因此您應該預計下一個評級將在2024年11月13日左右公佈。
Is the Analyst Rating Foghorn Therapeutics (FHTX) correct?
分析師對Foghorn Therapeutics（FHTX）的評級是否正確？
While ratings are subjective and will change, the latest Foghorn Therapeutics (FHTX) rating was a maintained with a price target of $10.00 to $6.00. The current price Foghorn Therapeutics (FHTX) is trading at is $3.23, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Foghorn Therapeutics（FHTX）評級維持不變，目標股價爲10.00美元至6.00美元。Foghorn Therapeutics（FHTX）目前的交易價格爲3.23美元，超出了分析師的預期區間。